BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics and safety of cefamandole in infants and children. 1978

C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans

Cefamandole, a new cephalosporin antibiotic, has greater activity against common pathogens, including Escherichia coli, Haemophilus influenzae, and Proteus (including indole-positive strains), than available cephalosporin drugs. We have evaluated the safety and pharmacokinetics of this drug in 30 infants and children. Blood levels and urinary excretion of the drug were similar to those previously found in adults. The only side effects were mild and transient elevation of serum glutamic oxalacetic transaminase in 12 patients and of blood urea nitrogen in 1 patient in whom serum creatinine remained normal and unchanged.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007232 Infant, Newborn, Diseases Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts. Neonatal Diseases,Disease, Neonatal,Diseases, Neonatal,Neonatal Disease
D008297 Male Males
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D002435 Cefamandole Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate. Cephamandole,Compound 83405
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans
Pharmacokinetics and safety of cefamandole in newborn infants.
May 1979, Antimicrobial agents and chemotherapy,
C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans
Pharmacokinetics of cefamandole in infants and children.
September 1978, Antimicrobial agents and chemotherapy,
C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans
Mezlocillin in infants and children: efficacy, safety and pharmacokinetics.
January 1982, The Journal of antimicrobial chemotherapy,
C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans
Clinical and laboratory evaluation of cefamandole in infants and children.
May 1978, The Journal of infectious diseases,
C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans
[Clinical evaluation of cefamandole in infants and children (author's transl)].
September 1979, The Japanese journal of antibiotics,
C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans
[Pharmacokinetics of cefamandole in rabbits].
December 1982, Antibiotiki,
C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans
Single-dose gabapentin pharmacokinetics and safety in healthy infants and children.
May 2001, Journal of clinical pharmacology,
C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans
Cefamandole: in vitro and clinical pharmacokinetics.
November 1976, Antimicrobial agents and chemotherapy,
C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans
Comparative pharmacokinetics of cefoperazone and cefamandole.
February 1981, Antimicrobial agents and chemotherapy,
C T Chang, and A J Khan, and M M Agbayani, and R Jhaveri, and I Amin, and H E Evans
Clinical and laboratory investigation of cefamandole in infections of infants and children.
June 1978, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!